Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 6
2010 6
2011 5
2012 5
2013 4
2014 5
2015 8
2016 11
2017 19
2018 21
2019 16
2020 16
2021 28
2022 17
2023 8
Text availability
Article attribute
Article type
Publication date

Search Results

148 results
Results by year
Filters applied: . Clear all
Page 1
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products.
Talarico R, Ramirez GA, Barreira SC, Cardamone C, Triggianese P, Aguilera S, Andersen J, Avcin T, Benistan K, Bertsias G, Bortoluzzi A, Bouillot C, Bulina I, Burmester GR, Callens S, Carreira PE, Cervera R, Cutolo M, Damian L, Della-Torre E, Faria R, Fonseca JE, Galetti I, Hachulla E, Iaccarino L, Jacobsen S, Khmelinskii N, Limper M, Marinello D, Meyer A, Moroncini G, Nagy G, Olesinska M, Pamfil C, Pileckyte M, Pistello M, Rednic S, Richez C, Romão VC, Schneider M, Sciascia S, Scirè CA, Simonini G, Smith V, Sulli A, Tani C, Tas SW, Tincani A, Vonk MC, Tektonidou M, Mosca M. Talarico R, et al. Among authors: richez c. Clin Exp Rheumatol. 2023 Mar 14. doi: 10.55563/clinexprheumatol/jpargp. Online ahead of print. Clin Exp Rheumatol. 2023. PMID: 36916322
Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study.
Lopez L, Barnetche T, Galli G, Seneschal J, Blanchard E, Shipley E, Pellegrin JL, Lazaro E, Constans J, Duffau P, Schaeverbeke T, Richez C, Kostine M, Truchetet ME. Lopez L, et al. Among authors: richez c. Joint Bone Spine. 2023 Feb 25;90(3):105555. doi: 10.1016/j.jbspin.2023.105555. Online ahead of print. Joint Bone Spine. 2023. PMID: 36842760
Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg.
Touret F, Martin-Blondel G, de Lamballerie X, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, N'Guyen S, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Barthélémy K, Priet S, Nurtop E, Sanchez VP, Tardivon C, Blancho G, Le Bourgeois A, Lévy V. Touret F, et al. Among authors: richez c. J Infect. 2023 Feb 5:S0163-4453(23)00071-3. doi: 10.1016/j.jinf.2023.02.002. Online ahead of print. J Infect. 2023. PMID: 36750165 No abstract available.
The role of platelets in immune-mediated inflammatory diseases.
Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. Scherlinger M, et al. Among authors: richez c. Nat Rev Immunol. 2023 Jan 27:1-16. doi: 10.1038/s41577-023-00834-4. Online ahead of print. Nat Rev Immunol. 2023. PMID: 36707719 Free PMC article. Review.
COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection.
Comarmond C, Drumez E, Labreuche J, Hachulla E, Thomas T, Flipo RM, Seror R, Avouac J, Balandraud N, Desbarbieux R, Felten R, Gilson M, Guyot MH, Hittinger-Roux A, Pham T, Renard M, Roux N, Sobanski V, Tournadre A, Richez C, Cacoub P; FAI2 R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Comarmond C, et al. Among authors: richez c. J Transl Autoimmun. 2023 Jan 14;6:100190. doi: 10.1016/j.jtauto.2023.100190. eCollection 2023. J Transl Autoimmun. 2023. PMID: 36684808 Free PMC article.
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).
Gottenberg JE, Chaudier A, Allenbach Y, Mekinian A, Amoura Z, Cacoub P, Cornec D, Hachulla E, Quartier P, Melki I, Richez C, Seror R, Terrier B, Devauchelle-Pensec V, Henry J, Gatfosse M, Bouillet L, Gaigneux E, Andre V, Baulier G, Saunier A, Desmurs M, Poulet A, Ete M, Bienvenu B, Truchetet ME, Michaud M, Larroche C, Dellal A, Leurs A, Ottaviani S, Nielly H, Vial G, Jaussaud R, Rouvière B, Jeandel PY, Guffroy A, Korganow AS, Jouvray M, Meyer A, Chatelus E, Sordet C, Felten R, Sibilia J, Litim-Ahmed-Yahia S, Kleinmann JF, Mariette X. Gottenberg JE, et al. Among authors: richez c. RMD Open. 2022 Nov;8(2):e002324. doi: 10.1136/rmdopen-2022-002324. RMD Open. 2022. PMID: 36319066 Free PMC article.
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study.
De La Fuente F, Belkhir R, Henry J, Nguyen CD, Pham T, Germain V, Gavand PE, Labadie C, Briere C, Lauret A, Cardon T, Mouterde G, Bonnet I, Rouxel L, Truchetet ME, Schaeverbeke T, Richez C, Kostine M; Club Rhumatismes and Inflammation (CRI). De La Fuente F, et al. Among authors: richez c. RMD Open. 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612. RMD Open. 2022. PMID: 36270747 Free PMC article.
Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation.
de Lamballerie X, Martin-Blondel G, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, le Bourgeois A, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, Guyen SN, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Sanchez VP, Tardivon C, Blancho G, Lévy V. de Lamballerie X, et al. Among authors: richez c. J Infect. 2023 Jan;86(1):66-117. doi: 10.1016/j.jinf.2022.10.006. Epub 2022 Oct 8. J Infect. 2023. PMID: 36216187 Free PMC article. No abstract available.
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A. Devauchelle-Pensec V, et al. Among authors: richez c. JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459. JAMA. 2022. PMID: 36125471 Clinical Trial.
148 results